Future Tech Ventures in the spotlight in Dagblad van het Noorden. Read the full article by Richold Brandsma, published today in the Dagblad.
The Groningen-Eindhoven startup Avoxt is working on a new type of electrolyzer. This electrolyzer contains no membranes. The advantage of such a membrane-free electrolyzer is that it can significantly reduce the production costs of hydrogen. Avoxt is the latest investment by Future Tech Ventures in Groningen. This new investment fund stems from the investment vehicles of UMCG (Triade), RUG (RUG Ventures), Investment Fund Groningen, and NOM.
The four organizations wanted to do more for newly founded startups, says fund manager Niek Huizenga. “Each of them occasionally invested in early-stage startups individually. Sometimes, this didn’t happen, causing highly innovative ideas to remain shelved.” This was the criticism frequently voiced by Prince Constantijn, special envoy for Techleap, regarding Dutch universities. In his view, the vast amount of knowledge within universities was not translating into sufficient value for society.
NOM, Triade, RUG Ventures, and Investment Fund Groningen joined forces with Future Tech Ventures. This strengthened the early financing of companies working on promising ideas or technologies.
Future Tech Ventures is well-funded. The fund holds €20 million (€10 million from the founders and €10 million from the Joint Transition Fund). Its goal is to fund fifty newly established companies over five years, helping them grow.
The demand for such funding was high. News about the fund had been circulating for some time, says Huizenga. “When we finally launched in September last year, we immediately had a list of 100 potential investments.”
The fund invests a maximum of €350,000 per company. However, not everyone with an idea is automatically guaranteed funding, explains investment manager Kyra Weaver.
The first requirement is that a company already exists—investment in mere projects is not an option. Additionally, the company must still be in the development phase, meaning it cannot yet be generating commercial revenue.
There must also be a clear connection to Groningen or Emmen (the JTF region). “We actively seek companies throughout the northern provinces, but their impact—such as job creation—must be in Groningen or Emmen. It is also essential that the company is working on something truly innovative.”
Future Tech Ventures invests at a stage when startups are further developing their technology. Huizenga explains, “We assess whether the technology has significant potential and whether the market is interested.”
A key part of this assessment is also the interest of potential follow-up investors. “We aim to support a company’s future development. With our investment, we want to help the company reach a phase where the next investor sees it as a worthwhile opportunity.”
Nine promising startups have already received funding from Future Tech Ventures. “Another ten are currently in the pipeline,” says Weaver.
Despite thorough preliminary research, investing remains a risk. These startups are still in their infancy. Of the fifty investments Future Tech Ventures aims to make, some will not reach the finish line.
“But we want to get innovation off the ground, and that means taking the leap sometimes,” says Huizenga. “Every company we support must have the ambition to grow and make an impact. But the reality is that some won’t make it. That’s a risk we accept within our fund. We give young companies the chance to start.”
How big is the problem that these companies are solving? Is their solution truly effective? And is the team capable of solving it?
Nine startups have successfully passed this test and are now supported by Future Tech Ventures. They have the potential to make an impact. Impact? Imagine saving thousands of children’s lives each year.
Some examples:
SeaO2: Developing technology to remove CO₂ from oceans—and indirectly, from the air. The captured CO₂ can either be stored or recycled.
Balto: Provides personalized support to patients in adhering to doctor-prescribed therapies.
Fused Button Battery: Every year, thousands of children worldwide die after swallowing button cell batteries. Fused Button Battery has developed technology to make these batteries safer.
IoniQS: IoniQS technology can recover lithium from wastewater, reducing the need for mining this critical resource and conserving water.
Source: Dagblad van het Noorden, Richold Brandsma
Who is developing the most impactful innovation in Life Sciences & Health in the Northern Netherlands? Five companies are in the running for the LIFE Science Innovation Award 2026: Flux Robotics, Limosa Immunodiagnostics, SPCTR, MimeCure and GlycanScan International. The nominees will present their innovations on Tuesday 22 September during the fifth edition of the LIFE Science Conference in Groningen. An independent jury will select the winner, who will receive a €10,000 cash prize.
A much-loved tradition The Campus Trail has become a much-loved tradition on campus. Students, employees and professionals from companies and organisations across the campus ecosystem lace up their running shoes for a sporty 6.4-kilometre route through buildings and past some of the campus’s unique labs. The rapid growth in registrations shows just how much the Campus Trail has become part of the campus community. The combination of sport, meeting others and the unique campus setting makes the run a great opportunity to connect with people outside the usual work and study environment. And there’s no need to head home as soon as you cross the finish line. During the after-party, hosted by Contini Catering, participants can relax together, enjoy a drink and celebrate the afternoon. There’s still time to join: those who want to take part can register online until 3 September, or sign up on the day itself using the PIN Campus Trail 2026 | Campus Groningen.
ZonMw is expected to open the final call for proposals within the PharmaNL Shared Development Infrastructure (SDI) program line. This program line focuses on strengthening the infrastructure for the development, upscaling, and production of innovative medicines in the Netherlands.
